ImmuPharma plc (LON:IMM – Get Free Report) was up 39.7% on Monday . The stock traded as high as GBX 7.14 ($0.09) and last traded at GBX 5.50 ($0.07). Approximately 53,455,387 shares changed hands during mid-day trading, an increase of 148% from the average daily volume of 21,559,516 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Stock Performance
The company has a 50-day simple moving average of GBX 1.92 and a two-hundred day simple moving average of GBX 1.78. The stock has a market cap of £20.74 million, a price-to-earnings ratio of -498.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- What is diluted earnings per share (Diluted EPS)?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- 3 Monster Growth Stocks to Buy Now
- 3 Steel Stocks Soaring After Tariff Announcements
- How to Invest in Biotech Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
